Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage biotechnology company aiming to transform cardiovascular disease treatment through innovative CRISPR-based gene-editing therapies.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

TD Cowen upgraded Crispr Therapeutics (CRSP) to Hold from Sell with an unchanged price target of $35. The firm continues to be cautious on the ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

LENZ Therapeutics (LENZ), Verve Therapeutics (VERV), Prime Medicine (PRME), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), and CRISPR Therapeutics (CRSP) were also among notable decliners.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks Consensus Estimate for quarterly sales is pegged at $10.13 million ...

Verve Therapeutics (VERV) shares rallied 18.7% in the last trading session to close at $7.80. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Verve Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $19.34. The stock has a market cap of $465.65 million, a P/E ratio of -2.24 and a beta of 1.68.